Emerging data suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , could offer a promising development for obesity management . Preliminary human trials have demonstrated impressive decreases in visceral tissue, possibly surpassing current weight-loss therapies . Despite this, further evalu